Oramed reaches 50% enrollment in late-stage oral insulin study

• Oramed Pharmaceuticals (NASDAQ:ORMP) has enrolled and randomized over 50% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
• Efficacy data for ORA-D-013-1 will become available after all patients have completed the first 6-month treatment period, the company said.
• The company said that it anticipates to announce topline results in 2022.